Healthcare / Medical DevicesKSE
$7480.00
-300.00 (-3.86%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 19%
FCF escenarios
weak_data · normalized FCF $75.6B · quality 45.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$894.8B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-22.0%
↓Gross Margin
45.8%
↓Debt/Equity
0.29
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-37.7%
FCF CAGR
-20.1%
FCF margin
42.2%
FCF / Net income
-0.59x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $710.58B · net income $-512.11B · FCF $300.03B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $710.58B | $710.58B | $694.57B | $655.68B | $2932.00B |
| Net Income | $-512.11B | $-512.11B | $-98.41B | $-467.71B | $911.36B |
| EBITDA | $-675.65B | $-675.65B | $-8.90B | $-251.85B | $1283.90B |
| EPS | — | — | -805.00 | -4219.00 | 8997.00 |
| Gross Margin | 45.8% | 45.8% | 48.9% | 19.2% | 47.5% |
| Operating Margin | -11.4% | -11.4% | -7.8% | -37.8% | 39.1% |
| Net Margin | -72.1% | -72.1% | -14.2% | -71.3% | 31.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.29 | 0.29 | 0.21 | 0.21 | 0.01 |
| Current Ratio | 5.07 | 5.07 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $300.03B | $300.03B | $75.62B | $-387.01B | $588.56B |
| Returns | |||||
| ROE | -22.0% | -22.0% | -3.4% | -16.6% | 31.0% |
| Valuation | |||||
| P/E | — | — | — | — | 3.41 |
| EV/EBITDA | — | — | — | — | 0.98 |
| P/B | 0.38 | 0.38 | 0.45 | 0.45 | 1.05 |
| Growth & Yield | |||||
| Revenue Growth | 2.3% | 2.3% | 5.9% | -77.6% | — |
| EPS Growth | — | — | 80.9% | -146.9% | — |
| Dividend Yield | 2.7% | 2.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-23.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-805.00 → n/d
Residual
-25.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.